Quarterly ResultAug 11, 2026, 04:04 PM
Aquestive Q2 Revenue $13.8M, Anaphylm NDA Resubmission on Track
AI Summary
Aquestive Therapeutics reported Q2 2026 total revenue of $13.8 million, a 38% increase year-over-year, driven by higher manufacture and supply revenue. The company's net loss widened to $22.9 million, primarily due to an $11.7 million one-time loss on extinguishment of debt. Non-GAAP adjusted EBITDA loss improved to $5.2 million. Strategically, Aquestive successfully completed human factors validation and pharmacokinetic studies for Anaphylm™, reaffirming its plan to resubmit the NDA to the FDA in Q3 2026 and begin ex-U.S. filings in Q4 2026.
Key Highlights
- Q2 2026 total revenue increased 38% to $13.8 million from $10.0 million in Q2 2025.
- Q2 2026 net loss was $22.9 million, or $0.18 per share, compared to $13.5 million in Q2 2025.
- Non-GAAP adjusted EBITDA loss improved to $5.2 million in Q2 2026 from $9.3 million in Q2 2025.
- Successfully completed human factors validation and pharmacokinetic studies for Anaphylm™.
- On track to resubmit Anaphylm NDA to the FDA in Q3 2026.
- Plans to begin ex-U.S. filings for Anaphylm in Q4 2026.
- Cash and cash equivalents were $98.5 million as of June 30, 2026.
- Manufactured approximately 48 million doses in Q2 2026, up from 37 million in Q2 2025.
Price Impact
More from AQST